Pharmaceutical intermediates
Adagrasib Intermediates
13 pharmaceutical intermediates for Adagrasib. Indication: Colorectal Cancer; Non-Small Cell Lung Cancer.
About Adagrasib
- Originator
- Mirati Therapeutics Inc; Array Biopharma
- Indication
- Colorectal Cancer; Non-Small Cell Lung Cancer
- Approved Date
- 12/12/2022
- NCE Patent
- 12/12/2027
- DS/DP
- 05/17/2037
Available intermediates
13 intermediates currently listed for Adagrasib. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| (S)-2-(Piperazin-2-yl)acetonitrile dihydrochloride | 2158301-19-8 | / | / |
| sodium 2-fluoroacrylate | 74893-46-2 | / | / |
| 8-chloronaphthalen-1-amine | 59107-51-6 | / | / |
| methyl 1-(8-chloronaphthalen-1-yl)-3-oxopiperidine-4-carboxylate | 2898538-56-0 | / | / |
| 7-(8-chloronaphthalen-1-yl)-2-mercapto-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-ol | 2898538-57-1 | / | / |
| 1-Bromo-8-chloronaphthalene | 20816-79-9 | / | / |
| tert-butyl 2,4-dichloro-5,6-dihydropyrido[3,4-d]pyrimidine-7(8H)-carboxylate | 916420-27-4 | / | / |
| 7-Benzyl-2,4-dichloro-5,6,7,8-tetrahydropyrido[3,4-d]pyriMidine | 1059735-34-0 | / | / |
| Ethyl N-benzyl-3-oxo-4-piperidine-carboxylate hydrochloride | 52763-21-0 | / | / |
| 7-(8-chloronaphthalen-1-yl)-2-(isopropylsulfonyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-ol | 2898538-61-7 | / | / |
| (S)-7-(8-chloronaphthalen-1-yl)-2-((1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-ol | 2408250-15-5 | / | / |
| 2-((S)-4-(7-(8-chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile | 2206737-06-4 | / | / |
| 2-FLUOROACRYLIC ACID | 430-99-9 | / | / |
Building toward Adagrasib?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →